Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
25.47
+0.01 (0.04%)
At close: Dec 5, 2025, 4:00 PM EST
25.25
-0.22 (-0.86%)
After-hours: Dec 5, 2025, 5:48 PM EST
Lyell Immunopharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lyell Immunopharma stock have an average target of 16.67, with a low estimate of 10 and a high estimate of 20. The average target predicts a decrease of -34.55% from the current stock price of 25.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lyell Immunopharma stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $10 → $20 | Hold | Maintains | $10 → $20 | -21.48% | Nov 24, 2025 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | -21.48% | Sep 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $10 | Hold | Maintains | $1 → $10 | -60.74% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -21.48% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -21.48% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
22.95K
from 61.00K
Decreased by -62.38%
Revenue Next Year
n/a
from 22.95K
EPS This Year
-11.28
from -26.23
EPS Next Year
-9.23
from -11.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31,500 | n/a | |||
| Avg | 22,950 | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -48.4% | - | |||
| Avg | -62.4% | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -10.71 | -7.72 | |
| Avg | -11.28 | -9.23 | |
| Low | -11.68 | -9.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.